Hyderabad: Indian Immunologicals Ltd produces Covaxin drug substance in record time

The batches produced at the IIL’s manufacturing facility have been tested by both Bharat Biotech and Indian Immunologicals Ltd and meet the quality specifications for the drug substance.

In order to augment the Covid-19 vaccine production capacity in the country so that a significant percentage of the population can get vaccinated at the earliest, in April 2021, the Central government requested Indian Immunologicals Ltd (IIL) and Bharat Biotech International Limited (BBIL) to join hands. In addition to this, a grant of Rs 60 crore towards enhancing production capabilities was also sanctioned to the Indian Immunologicals Ltd. The company commenced production in July 2021.